068270 KS

Celltrion Inc

Healthcare


Presented:04/18/2018
Price:₩284,500.00
Cap:$34.40B
Current Price:₩200,500.00
Cap:$37.61B

Presented

Date04/18/2018
Price₩284,500.00
Market Cap$34.40B
Ent Value$26.94B
P/E Ratio88.72x
Book Value₩19,468.31
Div Yield0%
Shares O/S133.03M
Ave Daily Vol1,771,281
Short IntN/A

Current

Price₩200,500.00
Market Cap$37.61B
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Publicly traded companies mentioned herein: Celltrion Inc (068270 KS), Celltrion Pharma Inc (068760 KS), Celltrion Healthcare Co (091990 KS)

Highlights

The presenter is short shares of Celltrion (068270 KS), a Korean biopharmaceuticals company that has enjoyed strong performance over the past year, but is now in a more challenged position. In January 2018, Celltrion shares started pulling back after it received a warning letter from the US FDA, citing concerns around its manufacturing process. Despite the pullback, the stock trades at “lofty” multiples: 50x EV/Sales, 100x EV/EBITDA, and 185x P/E today.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.